- Health A to Z
Healthline Premium Tools
Advertisement
Marketplace
|
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Cancer / Oncology Blood / Hematology MabThera is now available in the UK for relapsed and difficult-to-treat patients with chronic lymphocytic leukaemia ,1 the most common form of leukaemia.2,3,4 Rituximab in combination with chemotherapy halts the progression of the disease by 10 ...
|
|
... y members offering an in-depth overview of hematologic (blood) cancers, focusing on non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). To RSVP: townhallrsvp@wcpglobal.com or 877.488.6656 Directions:
|
|
... a change. This morning, the company announced positive results in testing its cancer drug Campath in patients with chronic lymphocytic leukemia (CLL). The drug is already approved to treat CLL as a monotherapy, but Genzyme is trying to expand its ...
|
|
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Cancer / Oncology ; Blood / Hematology ; Clinical Trials / Drug Trials Article Date: 25 Sep 2009 - 5:00 PDT Genzyme Corporation announced today that its randomized Phase 3 clinical trial investigating Campath in combination with Fludara in relapsed or refractory chronic lymphocytic ...
|
|
Treatment decisions are based on the type and subtype of leukemia.. Blood Cancer Treatment In India Blood Cancer - Treatment Overview The goal of treatment for Blood Cancer is to destroy the leukemia cells and allow normal cells to form in your bone marrow.
|
|
... Modified: Friday, September 18, 2009 at 7:12 a.m. Dear Dr. Donohue: My 54-year-old husband has been diagnosed with chronic lymphocytic leukemia. Please explain this disease and how it affects longevity. -- C.L. Dear C.L.: Leukemia is cancer of white ...
|
|
... MS. Alemtuzumab (trade name Campath) is available in the U.S. as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside the U.S. for the treatment of B-CLL in patients who have been treated with alkylating ...
|
|
Samantha is on my schedule today for her yearly physical. I know from her preliminary lab work that Samantha has a leukemia called CLL.
|
|
... Received 18 November 2008; Revised 11 June 2009; Accepted 17 June 2009; Published online 30 July 2009. Abstract As chronic lymphocytic leukemia (CLL) is characterized by overexpression of pro-survival BCL2, compounds that mimic its physiological ...
|
|
... 2009; Accepted 12 June 2009; Published online 30 July 2009. Abstract The two B-cell non-Hodgkin's lymphoma entities, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), show recurrent chromosomal gains of 3q25-q29, 12q13-q14 and ...
|
|
... 2009; Published online 30 July 2009. Abstract Rituximab-containing regimens are becoming a therapeutic standard in chronic lymphocytic leukemia (CLL), so that a validation of flow cytometric minimal residual disease (MRD) quantification (MRD flow) ...
|
|
... deacetylase inhibitors have recently been proposed as potential new therapies for hematological malignancies. Chronic lymphocytic leukemia (CLL) remains incurable despite the introduction of new treatments. CLL B cells are characterized by an ...
|
|
... was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). This prompted us to evaluate the use of these agents in frontline therapy. A total of 28 ...
|
|
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence 1Centre for Research and Technology Hellas, Institute of Agrobiotechnology, Thessaloniki, Greece 2Hematology Department and HCT Unit, G Papanicolaou Hospital, Thessaloniki, Greece 3Rudbeck Laboratory, ...
|
|
... Received 20 October 2008; Revised 12 June 2009; Accepted 17 June 2009; Published online 6 August 2009. Abstract Chronic lymphocytic leukemia (CLL) is a malignancy of mature B-lymphocytes that manifests in a variety of clinical courses. The ...
|
|
... multiple oncogenes, including BCL2 , MCL1 , CCND1 , and WNT3A . Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma. This review summarizes the discovery, functions, and ...
|
|
... , miR-34 , microRNA, SIRT1 Abbreviations: ATM, ataxia teleangiectasia mutated; CDK, cyclin-dependent kinase; CLL, chronic lymphocytic leukemia; CpG, cytosine-guanosine dinucleotide; HDAC, histone deacetylase; LNA, locked nucleic acids; LOH, loss of ...
|
|
Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia sik-Szczepanek 2 , A Bojarska-Junak 1 , J Rolinski 1 , H Dhner 3 , S Stilgenbauer 3 and L Bullinger 3 1Department of Clinical Immunology, Medical University of Lublin, Lublin, ...
|
|
... 0. These results suggest a favorable outcome for advanced CLL who undergo a RIC regimen compared with FIC. Keywords: chronic lymphocytic leukemia, reduced-intensity conditioning, full-intensity conditioning
|
Home | About | Health Experts | Careers | Site Map | Feedback | Help | Health Tools | Tell a Friend
Advertise | Terms of Use | Privacy Policy
Advertise | Terms of Use | Privacy Policy
Copyright © 2005 - 2009 Healthline Networks, Inc. All rights reserved.